课题基金 / 基金详情

TOPIC 438 - PREDICTION OF CANCER DRUG RESISTANCE TO AID IN CLINICAL DECISION MAKING

TOPIC 438 - PREDICTION OF CANCER DRUG RESISTANCE TO AID IN CLINICAL DECISION MAKING
主题 438 - 预测癌症耐药性以帮助临床决策
批准号:
10699945
负责人:
SUMAIRA ANDRABI
金额:
$40.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-01 至

项目摘要

项目成果

SUMAIRA ANDRABI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cancer is the second leading cause of death behind heart disease with ~600,000 deaths annually according to the CDC. Approximately 90% of cancer deaths are attributed to drug resistance making it a major health problem. Both intrinsic and acquired drug resistance in cancers have been attributed to the presence of genetic variant in the genes involved in growth or apoptosis. However, many of the variants found in patients’ tumor are of unknown significance. The proposed research develops a computational method that leverages machine learning applied to molecular dynamics simulations of wild-type and variant proteins that are drug targets to predict drug resistance and its severity. This quantitative information will be incorporated into protein network models describing cancer growth and apoptosis to predict how off-target variants can cause drug resistance through pathway interactions. This proposal brings together a collaborating team of experts in molecular simulation, machine learning, pathway modeling, software design and development and systems biology accomplishing this paradigm shifting work. At the conclusion of the proposed work, a prototype will be developed that can help oncologists and their team to understand and deliver information to patients about possible drug resistance in the patient’s tumor and to make clinical treatment decisions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TOPIC 438 - PREDICTION OF CANCER DRUG RESISTANCE TO AID IN CLINICAL DECISION MAKING
  • 批准号:
    10788020
  • 项目类别:
  • 资助金额:
    $5.5万
  • 财政年份:
    2022
  • 负责人:
    SUMAIRA ANDRABI
  • 依托单位:
海外基金